The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization for nitenpyram tablets to treat dogs, cats, puppies, and kittens infected with New World screwworm. This marks the first generic animal drug approved for screwworm treatment. The authorization follows recent documented cases of the flesh-eating pest in the U.S., prompting federal action.
Immediate Action & Core Facts
The FDA authorized nitenpyram, produced by Felix Pharmaceuticals, for pets weighing at least 2 pounds and older than 4 weeks. The drug works within hours of the first dose, with a second dose required six hours later. Pet owners must then consult a veterinarian to remove larvae and provide wound care. The over-the-counter tablets are available in 11.4 mg and 57 mg sizes, dosed by weight.
Deeper Dive & Context
Screwworm Threat and Response
New World screwworm flies lay eggs in open wounds or mucous membranes, with larvae burrowing into flesh, causing myiasis (larval infestation). The infestation can lead to severe illness or death. The FDA’s decision is part of broader efforts by the Trump administration to combat the outbreak, which has raised concerns about beef prices and livestock health.
Official Rationale
The FDA stated it has scientific evidence supporting nitenpyram’s effectiveness and that the benefits outweigh risks. U.S. Health and Human Services Secretary Robert F. Kennedy Jr. emphasized the government’s aggressive response to contain and eliminate the pest.
Treatment Protocol
Nitenpyram is administered in two doses, followed by veterinary intervention to remove larvae. The FDA’s authorization is temporary, pending further review. The drug’s availability aims to mitigate the spread of screwworm, which has not been seen in the U.S. for years.